Home
Scholarly Works
CANAGLIFLOZIN, A NEW ANTI-DIABETIC AGENT TARGETING...
Conference

CANAGLIFLOZIN, A NEW ANTI-DIABETIC AGENT TARGETING CELLULAR METABOLISM, SUPPRESSES SURVIVAL AND ENHANCES THE RESPONSE OF NON-SMALL CELL LUNG CANCER (NSCLC) TO RADIOTHERAPY

Authors

Biziotis O-D; Tsakiridis E-E; Broadfield L; Farrell T; Menjolian G; Mathurin T; Mekhaeil B; Zacharidis P; Muti P; Abdulkarim B

Volume

139

Pagination

pp. S20-S20

Publisher

ELSEVIER IRELAND LTD

Publication Date

October 1, 2019

Name of conference

Annual Scientific Meeting of the Canadian-Association-for-Radiation-Oncology (CARO)

Conference place

Halifax, CANADA

Conference start date

October 2, 2019

Conference end date

October 5, 2019

Conference proceedings

RADIOTHERAPY AND ONCOLOGY

ISSN

0167-8140

Contact the Experts team